Incorporating services for common mental disorders and substance use disorders for people living with HIV along the HIV treatment cascade

Thomas F. Kresina1*, Ilana F. Lapidos-Salaiz2, Elizabeth Lopez1 and Kimberly Johnson1

1Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, Rockville, Maryland, USA
2Office of HIV/AIDS, USAID, Washington, DC, USA

Abstract
The prevalence of common mental disorders (CMDs) and substance use disorders (SUDs) are higher in people living with HIV (PLHIV) than in the general population. Numerous studies have shown the high negative impact of these disorders on HIV clinical outcomes for PLHIV and the continued lack of services for CMDs and SUDs in HIV care and treatment programs, particularly in resource limited settings. The provision of services for CMDs/SUDs along the HIV care and treatment continuum provides a platform for better clinical outcomes that can substantially impact HIV epidemic control. Development and analysis of the HIV treatment cascade (number of PLHIV, number of diagnosed PLHIV, number PLHIV receiving antiretroviral treatment (ART), and number of PLHIV with suppressed viral load) for PLHIV with CMDs and SUDs can provide important data on the efficacy and impact of the services for CMDs and SUDs, as well as, reveal gaps in care and services. Integration or co-location into HIV primary care of effective evidence-based services for CMDs and SUDs provide the best platform for addressing both CMDs/SUDs and HIV infection for PLHIV.

Introduction

The World Health Organization (WHO) defines mental health as a fundamental component of personal health and well-being [1]. CMDs, as classified by the Diagnostic and Statistical Manual of Mental Disorders (DSM–5) [2] or by the International Classification of Diseases and Related Health Problems (ICD-10) [3], result in both disproportionately higher rates of disability and mortality, and account for up to 10% of the global burden of disease [4]. In addition, CMD occur in a higher prevalence in PLHIV, but remain under-diagnosed and poorly treated, particularly in low and middle income countries [5]. Globally, as reviewed in [6], the prevalence of CMDs occurring in PLHIV range from 20–35% for depression, 19–37% for anxiety disorders, 15–26% for post-traumatic stress disorders and 5-23% for severe mental illnesses. In addition, SUDs have been reported among 7–16% of PLHIV, all of which impact the care and treatment of HIV infection along the treatment cascade [6].

Common Mental Disorders and HIV Infection in Low and Middle Income Countries

When population based screening occurs, CMDs can be identified at higher rates in PLHIV compared to the general population [7-9]. WHO guidelines underscore that PLHIV in resource-limited settings may experience CMDs, and that HIV care settings provide the opportunity to screen for and manage common CMDs through a range of care and treatment options that include counseling and pharmacotherapy [9,10].

Depression and anxiety are common CMDs observed among PLHIV, particularly women [11-15]. Screening studies in African countries have reported the prevalence of depression in PLHIV ranging from 8-28% [14,16-19]. For anxiety disorders, screening studies have shown up to 5-fold increase in prevalence in PLHIV compared to the general population [19-21]. In low and middle income countries, female sex, older age, low education, low income, HIV infection, HIV stigma, and poverty are strongly associated with CMDs [22-26]. Other CMDs, that occur in higher prevalence in PLHIV than the general population are suicide and suicide ideation. Recent studies have reported suicide rates of 12- 20% and suicide ideation in roughly one in three PLHIV [27-29]. Risk factors for suicide attempts were marital status, HSV stigma, poor disease management and poor social support, while factors associated with suicide ideation were noted to be female sex, depression/anxiety, marital status, learning their HIV status and poor disease management. WHO recommends addressing psychological distress, the societal risk factors for suicide, augmenting protective factors, and ongoing monitoring of PLHIV as part of a comprehensive suicide prevention strategy. In addition, the use of the antidepressant, Amitriptyline, is recommended in low and middle income countries because of costs and availability to reduce the symptoms of depression (a precursor to suicide) as a component of care, specifically when emergency or rapid onset of action is required [9,10,30].

Substance Use Disorders and HIV Infection in Low and Middle Income Countries

Correspondence to: Thomas F. Kresina, PhD, Division of Pharmacologic Therapies, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, 5600 Parklawn Drive, Rockville, MD USA 20857; E-mail: tkresina@samhsa.gov

Key words: mental health, common mental disorders, HIV treatment cascade, depression, anxiety, suicide ideation, substance use disorders, alcohol use disorder, health services integration, retention in care, cost-effectiveness

Received: April 22, 2017; Accepted: May 15, 2017; Published: May 19, 2017
People who use drugs are at elevated risk for both SUDs and HIV infection. In the context of HIV infection, PLHIV who acquire a SUD are frequently disengaged from the healthcare system, thereby limiting their access to HIV services [31]. Creating an enabling care environment for people who use drugs, in a primary care setting, and co-locating treatment for SUDs and HIV infection is an evidence-based best practice that improves patient treatment service acquisition and outcomes [32,33]. In addition, integrating HIV and drug treatment services promotes the reengagement of people who use drugs who are lost to follow-up through the reduction of barriers to access care and treatment [33,34]. With integrated services, PLHIV can be screened for alcohol and drug use allowing for on-site services addressing harmful alcohol use and stimulant use which can enhance HIV transmission risk through sexual transmission or injection transmission [35-38]. Thus, alcohol-, opioid- and stimulant-use disorders are important co-morbidities of PLHIV to address as national HIV program plan to obtain epidemic control of HIV infection [38-43]. However, SUDs are not routinely screened for in HIV care and treatment settings, although highly prevalent in people who use drugs and who are seeking care. Opioid use disorders are recognized as a significant HIV risk factor for people who inject drugs and has been shown to be the largest contributor to disability-adjusted life years (DALYs) for PLHIV who use drugs [10,37,38,44,45].

SUDs can be addressed in a health care setting with interventions, such as screening and brief interventions with recovery management to reduce harmful use, as well as by therapies such as cognitive-behavioral therapy (CBT)/motivational enhancement therapy (MET), or through pharmacotherapy and medical management [46-52]. For people living with HIV with opioid dependence, treatment with medication assisted treatment (MAT) in HIV primary care improves the HIV–related outcomes of mortality, quality of life, retention in care, and antiretroviral treatment adherence [53]. WHO notes that substance-use disorders are highly prevalent, globally, and burdensome to society; but the gap between providing needed treatment and that which is locally available to reduce the burden of disease remains very wide [9]. WHO guidelines underscore the importance of HIV care settings that can provide the opportunity to screen for and manage common SUDs through a range of care and treatment options that include counseling and pharmacotherapy, i.e. MAT. The guidelines additionally urge that that these services be part of national HIV/AIDS programs, and integrated into primary care programs for PLHIV [9,10].

The HIV treatment cascade

The HIV treatment cascade, also called the HIV care cascade, is an analytic tool that measures the achievement status of a HIV program in obtaining the target goals of 90/90/90. 90/90/90 refers to the targets set by the Joint United Nations Programme on HIV/AIDS (UNAIDS) by 2020; 90% of all PLHIV will know their HIV status though HIV testing; by 2020, 90% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy; by 2020, 90% of all people receiving antiretroviral therapy will have achieved viral suppression [54].

Suppression of the HIV viral load is a surrogate marker for retention in care and medication adherence, since both are required to obtain viral load suppression. As shown in Figure 1, a standard cascade analytic tool provides a population estimate of the number of PLHIV; data comprising the number of individuals diagnosed with HIV infection, the number of PLHIV who are linked to/receiving antiretroviral treatment and the number of ART recipients obtaining a suppressed viral load. Various versions of the cascade can be generated using additional components of the HIV care continuum, as well as, specific populations and subpopulations as part of the analyses of epidemic control [55,56].

An important subpopulation for analysis of epidemic control is PLHIV with CMDs and/or SUDs. A recent review has provided data on 53 national care cascades comprising 54% of the global estimate of PLHIV [57]. The data show that 48% of the global estimate of PLHIV is receiving ART and of those, 40% are virally suppressed. However, only seven countries were noted to be nearing the 90/90/90 targets, with three African countries on track to epidemic control by 2030 [58]. Thus, the treatment cascade is an excellent tool to monitor treatment outcome and quantify PLHIV who are lost to care, and for those who remain in care but do not achieve a good clinical outcome, i.e. suppressed viral load [58,59]. Through the analysis of the cascade, a determination can be made for the need of interventions, through the HIV care continuum, that address programmatic gaps in care and facilitate good clinical outcomes [59-61]. Analyses include the need for interventions and services that provide for the treatment of CMDs and SUDs.

Services for common mental disorders and substance use disorders in HIV testing and counselling

Using established standard survey and surveillance methodology, as well as, data reporting, an estimate for the national prevalence of PLHIV, as well as other elements of the treatment cascade can be determined [62]. The WHO has developed guidelines for HIV testing services that provides guidance, policy and recommendation for HIV testing for various settings and for differing populations [63]. National HIV programs derive their HIV testing algorithm, which varies based on available technology, from this guidance. HIV testing algorithms form the basis for an HIV diagnosis. It is estimated that globally, between 54-60% of PLHIV have been tested and know their HIV status [57,63]. The common modalities for HIV testing are facility/provider-based testing, community-based testing and self-testing [63], each of which provides a setting for providing services for CMDs and SUDs. An important service that can be provided at the time of HIV testing is screening for common CMDs, such as depression and anxiety, as well as, screening for SUDs, harmful alcohol use and injection drug use [64]. One such screening in Kenya, using an acculturated, validated screening tool showed that 45% of those screened had a lifetime diagnosis of a common CMD with 15.7% an anxiety disorder, 12.3% a major depressive disorder; 11.7% a SUD, and 16.4% a life-time suicidal
Kresina TF (2017) Incorporating services for common mental disorders and substance use disorders for people living with HIV along the HIV treatment cascade

Ment Health Addict Res, 2017         doi: 10.15761/MHAR.1000137

There are multiple barriers for PLHIV to initiate ART that result from CMDs and SUDs. These barriers occur at the family and social level, at the health care system level and at the individual level [72,73]. Family and social barriers to initiating ART include disenfranchisement, banishment, homelessness, social discrimination; health care system barriers include poor enabling environment, stigma and discrimination and lack of mental health and drug treatment; individual barriers including low self-esteem, poor health knowledge, and low motivation to initiate ART. A recent study has shown that even in the era of ART for all PLHIV, health care providers deferred ART initiation for nearly one-in-three PLHIV due to the diagnosis of a common CMD or SUD [73]. Deferral of ART results in poor HIV clinical outcomes with an increase in lost-to-follow-up, as well as, increased mortality [74]. There are interventions for health care providers and the community, such as education and social contact, that have shown short-term gains in reducing the stigma associated with CMDs, but long term solutions remain elusive [75]. Stigma and discrimination associated with CMDs and SUDs remain a formidable barrier for PLHIV to access the health care system and initiate ART. Other important interventions to promote access to and retention in ART are treatment of CMDs and SUDs [76-79]. Effective, evidence-based treatments for CMDs and SUDs provide psychosocial support and patient stability creating a recovery platform promoting good clinical outcomes for long term ART. These treatments include both psychosocial therapy and pharmacotherapy [80-83]. Integration of treatment for CMDs and SUDs into HIV care and treatment programs results in good clinical outcomes and is cost effective [76,84-87]. Thus, patients in recovery from CMDs and SUDs can initiate ART successfully, adhere to pharmacological treatment regimens and over time, achieve an undetectable viral load, thereby contributing to epidemic control of HIV infection.

**Services for common mental disorders and substance use disorders in alternative models of HIV services delivery**

As the international HIV treatment guidelines change over time, ART clinics have responded by developing new models of HIV services delivery to meet both guideline changes and the increasing treatment targets [88,89]. These new service delivery models have the ultimate goals of increased treatment capacity and sustainable quality HIV service delivery in a cost-effective manner related to the resources available. The new models go beyond the traditional clinic-based, physician centered delivery of HIV services with changes and novel interventions to personnel with task shifting, service delivery locations into the community, modifying ART clinic follow-up appointment spacing and reducing criteria that limits enrollment into ART [89-91].

Service delivery models that reduce the frequency of follow-up clinic visits and provide community-based ART prescribing and refill programs or pharmacy refill only visits, as well as, non-clinic based platforms for ART support are intended to reduce HIV clinic congestion by limiting engagement in HIV primary care for stable PLHIV with an undetectable HIV viral load [89]. These models seek to increase the quality of HIV service delivery in clinics for those PLHIV who have more medical needs. PLHIV with CMDs and SUDs often have multiple co-morbidities along with medical and social needs that require complex medical and support services for good clinical outcomes [92,93]. Thus, the alternative models of HIV service delivery are a positive step in addressing the needs of PLHIV with CMDs and SUDs, if the needed services for these PLHIV are accessible and available. The needed services (Table 1) are also required long-term, since CMDs and SUDs are chronic, relapsing medical conditions. Based on the need for continued engagement with the health care system, integration of services for CMDs and SUDs along the HIV treatment cascade provides for optional clinical outcomes, is cost-effective, and impacts epidemic control of HIV infection [94,95].

**Summary**

CMDs and SUDs occur in a higher prevalence in PLHIV than in the general population, but remain under-diagnosed and poorly treated, particularly in low and middle income countries. Services for CMDs and SUDs are important for PLHIV along the HIV treatment cascade to obtain good clinical outcomes. The HIV treatment cascade of PLHIV with CMDs and SUDs can inform national HIV programs on the impact of the services on HIV epidemic control and the need to augment services for these subpopulations to obtain epidemic control. Integration or co-location of effective evidence-based services for CMDs and SUDs into HIV primary care in the context of the new

<table>
<thead>
<tr>
<th>Cascade Stage</th>
<th>Service for common mental disorders/Substance Use Disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV diagnosis</td>
<td>screening and brief intervention/brief therapy, MAT peer support with navigation and case management suicide prevention services</td>
</tr>
<tr>
<td>ART initiation</td>
<td>screening and brief intervention/brief therapy, MAT co-located/integrated pharmacologic &amp; psychosocial treatment social and peer group support/recovery services suicide prevention services</td>
</tr>
<tr>
<td>Virally suppressed</td>
<td>relapse prevention services, MAT social and peer group support/recovery services</td>
</tr>
</tbody>
</table>

Table 1. Services for common mental disorders and substance use disorders for people living with HIV along the HIV treatment cascade
service delivery models provide the best platform for addressing both CMDs/SUDs and HIV infection for PLHIV.

Disclaimer

The authors’ views expressed in this manuscript do not necessarily reflect the views of USAID or the US Government.

References

80. Himelhoch S, Medoff DR (2005) Efficacy of antidepressant medication among HIV-positive individuals with depression: a systematic review and meta-analysis. AIDS Patient Care STDS 19: 813–822. [Crossref]

81. Himelhoch S, Medoff DR, Oyeniyi G (2007) Efficacy of group psychotherapy to reduce depressive symptoms among HIV-infected individuals: a systematic review and meta-analysis. AIDS Patient Care STDS 21:732–739. [Crossref]


84. Adams JL, Gaynes BN, McGuinness T, Modi R, Willig J, et al. (2012) Treating depression within the HIV “medical home”: a guided algorithm for antidepressant management by HIV clinicians. AIDS Patient Care STDS 26: 647–654. [Crossref]


89. Zakumumpa H, Bennett S, Ssengooba F (2017) Modifications to ART service delivery models by health facilities in Uganda in promotion of intervention sustainability: a mixed methods study. Implement Sci 12: 45. [Crossref]


91. Callaghan M1, Ford N, Schneider H (2010) A systematic review of task-shifting for HIV treatment and care in Africa. Hum Resour Health 8: 8. [Crossref]


